Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease

Leucine rich repeat kinase 2 (LRRK2) mutations are a common cause of Parkinson’s disease (PD). Here, we identify inhibitors of LRRK2 kinase, which are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byoung Dae, Shin, Joo-Ho, VanKampen, Jackalina, Petrucelli, Leonard, West, Andrew B., Ko, Han Seok, Lee, Yun, Maguire-Zeiss, Kathleen A., Bowers, William J., Federoff, Howard J., Dawson, Valina L., Dawson, Ted M.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935926/
https://www.ncbi.nlm.nih.gov/pubmed/20729864
http://dx.doi.org/10.1038/nm.2199
Descripción
Sumario:Leucine rich repeat kinase 2 (LRRK2) mutations are a common cause of Parkinson’s disease (PD). Here, we identify inhibitors of LRRK2 kinase, which are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of PD.

Ejemplares similares